抗中性粒细胞胞浆抗体相关性血管炎患者接种第三剂BNT162b2新冠疫苗。 - Suppr

Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis.

作者信息

Speer Claudius, Töllner Maximilian, Benning Louise, Klein Katrin, Bartenschlager Marie, Nusshag Christian, Kälble Florian, Reichel Paula, Schnitzler Paul, Zeier Martin, Morath Christian, Schmitt Wilhelm H, Bergner Raoul, Bartenschlager Ralf, Schaier Matthias

机构信息

Nephrology, University Hospital Heidelberg, Heidelberg, Germany

Molecular Medicine Partnership Unit Heidelberg, European Molecular Biology Laboratory, Heidelberg, Baden-Württemberg, Germany.

出版信息

Ann Rheum Dis. 2022 Apr;81(4):593-595. doi: 10.1136/annrheumdis-2021-221747. Epub 2022 Jan 10.

DOI:10.1136/annrheumdis-2021-221747

PMID:35012926

Abstract

摘要

相似文献

Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis.抗中性粒细胞胞浆抗体相关性血管炎患者接种第三剂BNT162b2新冠疫苗。

Ann Rheum Dis. 2022 Apr;81(4):593-595. doi: 10.1136/annrheumdis-2021-221747. Epub 2022 Jan 10.

Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信

Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.

BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.BNT162b2 疫苗诱导红斑狼疮患者针对 SARS-CoV-2 变异株的体液和细胞应答。

Ann Rheum Dis. 2022 Apr;81(4):575-583. doi: 10.1136/annrheumdis-2021-221097. Epub 2021 Oct 4.

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据

Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.

A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.在 COVID-19 患者中接种一剂 mRNA 疫苗可提高针对 SARS-CoV-2 及关注变异株的中和抗体。

Cell Rep Med. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486. eCollection 2022 Jan 18.

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.接种 BNT162b2 mRNA COVID-19 疫苗后对原发性免疫缺陷患者的体液和细胞免疫反应。

Front Immunol. 2021 Oct 4;12:727850. doi: 10.3389/fimmu.2021.727850. eCollection 2021.

Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。

Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.肾移植受者对 SARS-CoV-2 mRNA 疫苗的抗体反应：一项前瞻性队列研究。

Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4. doi: 10.1016/j.cmi.2021.04.028. Epub 2021 May 3.

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.第三剂 BNT162b2 疫苗可诱导先前无反应的老年人群产生针对 SARS-CoV-2 的强大细胞和体液免疫。

Nat Microbiol. 2022 Feb;7(2):195-199. doi: 10.1038/s41564-021-01046-z. Epub 2022 Jan 10.

Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.评估 BNT162b2 SARS-CoV-2 疫苗在医护人员、老年人和自身免疫性疾病免疫抑制患者中诱导的体液和细胞免疫。

Immunol Res. 2021 Dec;69(6):576-583. doi: 10.1007/s12026-021-09226-z. Epub 2021 Aug 21.

引用本文的文献

Immunologic Response and Effects of COVID-19 Vaccines in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.抗中性粒细胞胞浆抗体相关性血管炎患者的免疫反应及新冠病毒疫苗的影响

Yonsei Med J. 2025 May;66(5):259-268. doi: 10.3349/ymj.2024.0129.

Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.反复接种 SARS-CoV-2 疫苗后微流控抗体分析显示，在接受抗 CD20 治疗的患者中，抗体亲和力和浓度与免疫受损和变异逃逸有关。

Front Immunol. 2024 Jan 8;14:1296148. doi: 10.3389/fimmu.2023.1296148. eCollection 2023.

Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study.类风湿关节炎患者接种第三剂新冠病毒mRNA疫苗后的免疫调节剂与突破性感染风险：一项队列研究

medRxiv. 2023 Oct 9:2023.10.08.23296717. doi: 10.1101/2023.10.08.23296717.

BA.1/BA.5 Immunogenicity, Reactogenicity, and Disease Activity after COVID-19 Vaccination in Patients with ANCA-Associated Vasculitis: A Prospective Observational Cohort Study.COVID-19 疫苗接种后抗中性粒细胞胞质抗体相关性血管炎患者的 BA.1/BA.5 免疫原性、反应原性和疾病活动情况：一项前瞻性观察性队列研究。

Viruses. 2023 Aug 21;15(8):1778. doi: 10.3390/v15081778.

Systemic Lupus Erythematosus and COVID-19.系统性红斑狼疮与 COVID-19。

Curr Rheumatol Rep. 2023 Oct;25(10):192-203. doi: 10.1007/s11926-023-01110-z. Epub 2023 Jul 21.

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV.系统文献回顾为 2022 年更新 EULAR 关于抗中性粒细胞胞浆抗体相关性血管炎（AAV）管理的建议提供信息：第 2 部分 - 嗜酸性肉芽肿性多血管炎的治疗和 AAV 的诊断与一般管理。

RMD Open. 2023 Jun;9(2). doi: 10.1136/rmdopen-2023-003083.

Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.COVID-19 时期血管炎患者的免疫抑制管理。

Rheum Dis Clin North Am. 2023 Aug;49(3):695-711. doi: 10.1016/j.rdc.2023.03.007. Epub 2023 Mar 14.

Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.利妥昔单抗治疗的风湿患者在接种 SARS-CoV-2 疫苗后持续的细胞介导而不是体液反应。

Rheumatology (Oxford). 2024 Feb 1;63(2):534-541. doi: 10.1093/rheumatology/kead236.

Attitudes and concerns regarding booster dose of COVID-19 vaccine among Egyptian patients with autoimmune and rheumatic diseases: a cross-sectional survey study.埃及自身免疫性和风湿性疾病患者对新冠病毒疫苗加强针的态度和担忧：一项横断面调查研究

J Pharm Policy Pract. 2023 Apr 5;16(1):54. doi: 10.1186/s40545-023-00558-9.

Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid.在短期停用霉酚酸后，既往无反应的肾移植受者对SARS-CoV-2 mRNA疫苗的体液反应。

Front Med (Lausanne). 2022 Aug 18;9:958293. doi: 10.3389/fmed.2022.958293. eCollection 2022.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献